Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Analysis of the Human Plasma Proteome Using Multi-Nanoparticle Protein Corona for Detection of Alzheimer's Disease Publisher Pubmed



Corbo C1, 2 ; Li AA3 ; Poustchi H4 ; Lee GY1 ; Stacks S1 ; Molinaro R5 ; Ma P6 ; Platt T6 ; Behzadi S1 ; Langer R7 ; Farias V8 ; Farokhzad OC1
Authors
Show Affiliations
Authors Affiliations
  1. 1. Center for Nanomedicine, Department of Anesthesiology, Brigham and Women's Hospital, Harvard Medical School, Boston, 02115, MA, United States
  2. 2. School of Medicine and Surgery, Nanomedicine Center Nanomib, University of Milano-Bicocca, Vedano al Lambro, 20854, Italy
  3. 3. Tepper School of Business, Carnegie Mellon University, Pittsburgh, 15213, PA, United States
  4. 4. Digestive Oncology Research Center, Digestive Disease Research Institute, Tehran University of Medical Sciences, Tehran, 4117-13135, Iran
  5. 5. Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, 77 Avenue Louis Pasteur, Boston, 02115, MA, United States
  6. 6. Seer, Inc., 3800 Bridge Parkway, Redwood City, 94065, CA, United States
  7. 7. Koch Institute for Integrative Cancer Research at MIT, Cambridge, 02139-4307, MA, United States
  8. 8. Sloan School of Management, Massachusetts Institute of Technology, Cambridge, 02142, MA, United States

Source: Advanced Healthcare Materials Published:2021


Abstract

As the population affected by Alzheimer's disease (AD) grows, so does the need for a noninvasive and accurate diagnostic tool. Current research reveals that AD pathogenesis begins as early as decades before clinical symptoms. The unique properties of nanoparticles (NPs) may be exploited to develop noninvasive diagnostics for early detection of AD. After exposure of NPs to biological fluids, the NP surface is altered by an unbiased but selective and reproducible adsorption of biomolecules commonly referred to as the biomolecular corona or protein corona (PC). The discovery that the plasma proteome may be differentially altered during health and disease leads to the concept of disease-specific PCs. Herein, the disease-specific PCs formed around NPs in a multi-NPs platform are employed to successfully identify subtle changes in plasma protein patterns and detect AD (>92% specificity and ≈100% sensitivity). Similar discrimination power is achieved using banked plasma samples from a cohort of patients several years prior to their diagnosis with AD. With the nanoplatform's analytic ability to analyze pathological proteomic changes into a disease-specific identifier, this promising, noninvasive technology with implications for early detection and intervention could benefit not only patients with AD but other diseases as well. © 2020 Wiley-VCH GmbH